文献速递产科母胎医学

17-羟孕酮己酸酯血浆浓度与早产分娩时孕周的关系

Relationship between plasma concentration of 17-hydroxyprogesterone caproate and gestational age at preterm delivery.
PubMed 文献 · Am J Obstet Gynecol MFM · 2023-04-24

本研究纳入有既往自发性早产史的两个队列,一个队列(n=143)随机分配至250 mg或500 mg 17-羟孕酮己酸酯,另一队列(n=16)常规接受250 mg剂量。结果显示,妊娠26至30周稳态 trough 血浆浓度随剂量成比例增加,药物浓度与自发性早产率无关(OR 1.00,95%CI 0.93-1.08),但与早产分娩时孕周显著相关;入组后宫颈环扎术是自发性早产和孕龄的强预测因素;500 mg与250 mg剂量不良事件相似。

要点

  • 17-羟孕酮己酸酯 trough 血浆浓度与自发性早产率无关(OR 1.00,95%CI 0.93-1.08)。
  • 药物浓度与首次给药至分娩间隔及26-30周采血至分娩间隔均显著相关。
  • 入组后宫颈环扎术是自发性早产(OR 4.03)和孕龄的强预测因素。

核心结论

  • 本药效学研究显示,17-羟孕酮己酸酯 trough 血浆浓度与早产分娩时孕周显著相关,但与早产率无关;入组后宫颈环扎术是自发性早产率和孕龄的强预测因素;初始宫颈长度可预测入组后宫颈环扎术风险;500 mg与250 mg剂量不良事件相似。

研究设计与样本

  • 本研究为药效学研究,招募两个有既往自发性早产史的队列;一个队列(n=143)随机分配至250 mg或500 mg 17-羟孕酮己酸酯,另一队列(n=16)常规接受250 mg剂量。
  • 于妊娠26至30周获取稳态 trough 血浆浓度,并与剂量、自发性早产率及孕龄指标进行相关性分析;同时按剂量评估母婴安全性结局。

主要发现

  • trough 血浆浓度随剂量成比例增加:250 mg组中位数8.6 ng/mL(n=66),500 mg组中位数16.2 ng/mL(n=55)。
  • 在116例有血样的依从参与者中,药物浓度与自发性早产率无关(OR 1.00,95%CI 0.93-1.08)。
  • 药物浓度与首次给药至分娩间隔(interval A:系数1.11,95%CI 0.00-2.23,P=.05)及26至30周采血至分娩间隔(interval B:系数1.56,95%CI 0.25-2.87,P=.02)均显著相关。
  • 自发性早产率或孕龄指标与剂量无关;入组后宫颈环扎术是自发性早产的强预测因素(OR 4.03,95%CI 1.24-13.19,P=.021),且与interval A(系数-14.9,95%CI -26.3至-3.4,P=.011)和interval B(系数-15.9,95%CI -25.8至-5.9,P=.002)均相关。
  • 初始宫颈长度与入组后宫颈环扎术风险显著相关(OR 0.80,95%CI 0.70-0.92,P=.001)。

关键数值与推荐

  • trough 血浆浓度与自发性早产率无关:OR 1.00(95%CI 0.93-1.08)。
  • 药物浓度与interval A相关:系数1.11(95%CI 0.00-2.23,P=.05);与interval B相关:系数1.56(95%CI 0.25-2.87,P=.02)。
  • 入组后宫颈环扎术预测自发性早产:OR 4.03(95%CI 1.24-13.19,P=.021)。
  • 入组后宫颈环扎术与interval A相关:系数-14.9(95%CI -26.3至-3.4,P=.011);与interval B相关:系数-15.9(95%CI -25.8至-5.9,P=.002)。
  • 初始宫颈长度预测入组后宫颈环扎术风险:OR 0.80(95%CI 0.70-0.92,P=.001)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The effectiveness of 17-hydroxyprogesterone caproate is unclear as trials have provided conflicting results. With the absence of fundamental pharmacologic studies addressing dosing or the relationship between drug concentration and gestational age at delivery, the effectiveness of the medication cannot be evaluated. OBJECTIVE: This study aimed to evaluate the relationship between plasma concentrations of 17-hydroxyprogesterone caproate and preterm birth rates and gestational age at preterm delivery and to assess the safety of the 500-mg dose. STUDY DESIGN: This study recruited 2 cohorts with previous spontaneous preterm birth; 1 cohort (n=143) was randomly assigned to either 250-mg or 500-mg 17-hydroxyprogesterone caproate, and the other cohort (n=16) was receiving the 250-mg dose for routine care. Steady-state trough plasma concentrations of 17-hydroxyprogesterone caproate obtained at 26 to 30 weeks of gestation were correlated to dose, spontaneous preterm birth rates, and measures of gestational length. Furthermore, maternal and neonatal safety outcomes were evaluated according to dose. RESULTS: There was a dose proportional increase in trough plasma concentrations with the 250-mg (median, 8.6 ng/m; n=66) and 500-mg (median, 16.2 ng/mL; n=55) doses. In 116 compliant participants with blood samples, drug concentration was not related to the spontaneous preterm birth rate (odds ratio, 1.00; 95% confidence interval, 0.93-1.08). However, there was a significant relationship between drug concentration and both the interval from the first administration to delivery (interval A: coefficient, 1.11; 95% confidence interval, 0.00-2.23; P=.05) and the interval from the 26- to 30-week blood draw to delivery (interval B: coefficient, 1.56; 95% confidence interval, 0.25-2.87; P=.02). The spontaneous preterm birth rate or measures of gestational length were not related to dose. Postenrollment cerclage adversely affected all pharmacodynamic assessments because it was a powerful predictor of spontaneous preterm birth (odds ratio, 4.03; 95% confidence interval, 1.24-13.19; P=.021) and both measures of gestational length (interval A [coefficient, -14.9; 95% confidence interval, -26.3 to -3.4; P=.011] and interval B [coefficient, -15.9; 95% confidence interval, -25.8 to -5.9; P=.002]). Initial cervical length was significantly related to the risk of postenrollment cerclage (odds ratio, 0.80; 95% confidence interval, 0.70-0.92; P=.001). Maternal and neonatal safety outcomes were similar in both dosing groups. CONCLUSION: In this pharmacodynamic study, trough plasma 17-hydroxyprogesterone caproate concentrations were significantly associated with gestational age at preterm birth but not with the preterm birth rate. Postenrollment cerclage was a powerful predictor of spontaneous preterm birth rate and gestational length. Initial cervical length predicted the risk of postenrollment cerclage. Adverse events were similar with the 500-mg and 250-mg doses of 17-hydroxyprogesterone caproate.

来源:Am J Obstet Gynecol MFM,查看原文。版权归原作者所有。

引用

  1. Caritis SN, Costantine MM, Clark S, et al. Relationship between plasma concentration of 17-hydroxyprogesterone caproate and gestational age at preterm delivery. Am J Obstet Gynecol MFM. 2023. PMID: 37100349. doi:10.1016/j.ajogmf.2023.100980

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。